The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Xtandi demonstrates significant improvement in OS in nmCRPC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, demonstrated a statistically significant improvement in overall survival in patients with nmCRPC who were treated with Xtandi plus ADT.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
By Ashley Cannon
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account